Clinical Trial Update: Study of the Safety and Efficacy of Fixed-dose Brexpiprazole (OPC-34712) as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder With and Without Anxious Distress [Phase 3]

View source ↗

Summary

Phase 3 study evaluating fixed-dose brexpiprazole as adjunctive therapy in adults with major depressive disorder with and without anxious distress; study comple…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Depressive Disorder
• Major Depressive Disorder
• Mood Disorders

Drugs mentioned

• brexpiprazole (brexpiprazole)

Snippet

Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc. | Conditions: Depressive Disorder, Depression | Phase 3 | Status: COMPLETED | Results posted: 2018-08-21